Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

Group 1 - Regeneron Pharmaceuticals, Inc. is recognized as one of the best affordable biotech stocks to invest in currently [1] - The company announced positive results from Phase 3 trials for its investigational allergen-blocking antibodies targeting cat and birch allergies, meeting primary and key secondary endpoints [1] - Data from these Phase 3 trials will be presented at an upcoming medical conference, indicating potential for future growth [1] Group 2 - Regeneron develops therapies for various diseases, including cancer, eye disorders, and allergic conditions [2] - The company has primarily relied on two products, Dupixent and Eylea, for revenue growth; Dupixent is co-marketed with Sanofi, while Eylea is co-marketed with Bayer [3]